Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

310 results found

2022 ∙ Sabbar, H. Mahraoui, C. Bastìas Garcià, M. Jroundi, I.

Streptococcus pneumoniae vaccination strategies and its expected impact on penicillin non-susceptibility in children under the age of five: Let's recap!

  • Newborn
  • Children
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Tantawichien, T. Hsu, L. Y. Zaidi, O. Bernauer, M. Du, F. Yamada, E. Kim, J. O. Sukarom, I.

Systematic literature review of the disease burden and vaccination of pneumococcal disease among adults in select Asia-Pacific areas

  • South-East Asia
  • Western Pacific
  • Adults
  • Older adults
  • Pneumococcal disease
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2022 ∙ Izurieta, P. Scherbakov, M. Nieto Guevara, J. Vetter, V. Soumahoro, L.

Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media

  • Newborn
  • Children
  • Adolescents
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Castrejon, M. M. Leal, I. de Jesus Pereira Pinto, T. Guzmán-Holst, A.

The impact of COVID-19 and catch-up strategies on routine childhood vaccine coverage trends in Latin America: A systematic literature review and database analysis

  • Americas
  • All age groups
  • Diphtheria
  • Pertussis
  • Tetanus
  • Hepatitis B
  • Haemophilus influenzae type B
  • Poliomyelitis
  • Measles
  • Rotavirus
  • Pneumococcal disease
  • Tuberculosis
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2022 ∙ Bollaerts, K. Fletcher, M. A. Suaya, J. A. Hanquet, G. Baay, M. Gessner, B. D.

Vaccine-Preventable Disease Incidence Based on Clinically, Radiologically, and Etiologically Confirmed Outcomes: Systematic Literature Review and Re-analysis of Pneumococcal Conjugate Vaccine Efficacy Trials

  • Newborn
  • Older adults
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022

Recommendations from the Higher Council for Infectious Diseases for vaccination against pneumococcus for populations at risk adults (18 years and over) or aged 65 and over

  • Recommendation
  • Europe
  • Luxembourg
  • Pneumococcal disease
Download:
2022 ∙ ACIP

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

  • Recommendation
  • Americas
  • United States of America
  • Adults
  • Pneumococcal disease
Download:
2022 ∙ ACIP

Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

  • Recommendation
  • Americas
  • United States of America
  • Children
  • Adolescents
  • Pneumococcal disease
Download:
2022 ∙ UNITAG

Advisory on switching PCV products from PCV10 – Synflorix to PCV10 - Pneumosil in Uganda’s routine immunization schedule

  • Recommendation
  • Africa
  • Uganda
  • Pneumococcal disease
Download:
2022 ∙ Conseil Supérieur de la Santé (CSS)

Vaccination against pneumococcal disease for adults in Belgium

  • Recommendation
  • Europe
  • Belgium
  • Risk group
  • Pneumococcal disease
Download:
Loading...